Menu

Category: Regulatory Science

CPTR 2017 Workshop: Summaries, Slides, and Videos — Day 4

Welcoming Remarks Marco Schito (Critical Path Institute) Marco Schito kicked off the final day of CPTR’s 2017 Workshop by affirming the essential role of diagnostics in effective TB treatment, and contrasting that importance with a lack of corresponding investment in the field, despite such a compelling value proposition. Schito outlined reasons why diagnostic development has […]

May 17, 2017 Drug Development Events RDST Regulatory Science Research Resources Assay Development biomarkers clinical trials Community Engagement CPTR Workshop 2017 diagnostics drug development drug resistance fluroquinolones hollow fiber model next-generation sequencing ReSeq TB ReseqTB TB-PACTS

CPTR 2017 Workshop: Summaries, Slides, and Videos — Day 3

Welcoming Remarks Jim Gallarda (Bill & Melinda Gates Foundation) Jim Gallarda opened the day’s agenda by reminding participants of the importance of collaboration and that silos often act as the largest impediments to progress in global health. Video     Keynote Address: Learning from the Impact of the Drug-Diagnostic Development Strategy in Oncology Jan Trost […]

May 17, 2017 Drug Development Events RDST Regulatory Science Research Resources Assay Development biomarkers clinical trials Community Engagement CPTR Workshop 2017 diagnostics drug development drug resistance fluroquinolones hollow fiber model next-generation sequencing ReSeq TB ReseqTB TB-PACTS

CPTR 2017 Workshop: Summaries, Slides, and Videos — Day 2

Welcoming Remarks Mel Spigelman (TB Alliance) Mel Spigelman opened the second day of the workshop by introducing the day’s agenda and drawing attention to the personal stories of TB patients, reinforcing the driving force behind CPTR and all TB research and development efforts. Video   Driving Progress Through Regulatory Innovation – Learnings from Oncology and […]

May 17, 2017 Drug Development Events RDST Regulatory Science Research Resources Uncategorized Assay Development biomarkers clinical trials Community Engagement CPTR Workshop 2017 diagnostics drug resistance fluroquinolones hollow fiber model ReSeq TB TB-PACTS

CPTR 2017 Workshop: Summaries, Slides, and Videos — Day 1

Welcoming Remarks Jan Gheuens (Bill & Melinda Gates Foundation) & Debra Hanna (Critical Path Institute) Jan Gheuens opened the event by reflecting on the growth and progress of the CPTR Initiative, as well as forward to its ongoing work. He stressed that the direction of CPTR is truly determined by those who participate it in, […]

May 17, 2017 Drug Development Events RDST Regulatory Science Research Resources Assay Development biomarkers clinical trials Community Engagement CPTR Workshop 2017 diagnostics drug development drug resistance fluroquinolones next-generation sequencing ReSeq TB ReseqTB TB-PACTS

2017 CPTR Annual Workshop to be Held March 20 – 23 in Washington DC

The 2017 Critical Path to TB Drug Regimens (CPTR) Annual Workshop, will be held March 20-23, 2017, in Washington DC. DATE: Monday, March 20 through Thursday, March 23, 2017 LOCATION: Washington, DC – Washington Marriot at Metro Center | 775 12th Street NW | 20005 Engaging panel sessions are being developed to showcase the exciting […]

October 12, 2016 Drug Development Events RDST Regulatory Science Research Resources Assay Development CPTR Workshop 2017 drug development

CPTR Workshop 2016: Full Content Day 4

Opening Remarks Speaker: Marco Schito, Critical Path Institute March Schito opened the last day of the CPTR 2016 Workshop recapping the progresses and challenges relating to DST development and summarizing the diagnostic development pathway. Schito shared insight on the future of DST, including the need for new policies to support the work and implementation of […]

May 3, 2016 Drug Development RDST Regulatory Science Research Resources Assay Development clinical trials CPTR Workshop 2016 drug development ReSeq TB

CPTR Workshop 2016: Full Content Day 3

Opening Remarks Speaker: Jim Gallarda, Bill & Melinda Gates Foundation Jim Gallarda set the stage for the day by considering how success in improved diagnostics should be defined, and stressing the need for innovation from both the supply (developers) side and the demand (users, uptake, and implementers) side. Gallarda emphasized that incentives are needed on […]

May 2, 2016 Drug Development RDST Regulatory Science Research Resources Assay Development clinical trials CPTR Workshop 2016 drug development ReSeq TB

CPTR Workshop 2016: Full Content Day 2

Welcoming Remarks Speaker: Mel Spigelman, TB Alliance Mel Spigelman opened the day’s program by reflecting on the changing landscape of TB drug development from a sponsor perspective. Noting that the new drugs themselves are the “beef” of the CPTR initiative, he commented that the current state of TB research has seen the retreat of some […]

May 2, 2016 Drug Development RDST Regulatory Science Research Resources Assay Development clinical trials CPTR Workshop 2016 drug development ReSeq TB

CPTR Workshop 2016: Full Content Day 1

Opening Remarks Speaker: Jan Gheuens, Bill & Melinda Gates Foundation Jan Gheuens opened CPTR’s 2016 Workshop by reminding the audience of the principles and mission of the CPTR Initiative, stressing the urgency of accelerating the development and availability of new TB combination therapies and noting the role of partnership and coordination in achieving the mission. […]

May 2, 2016 Drug Development RDST Regulatory Science Research Resources Assay Development clinical trials Community Engagement CPTR Workshop 2016 drug development

New TB Clinical Trial Data-Sharing Platform Available for Researchers

TUCSON, Ariz., April 18, 2016 — The Critical Path Institute (C-Path), the Special Programme for Research and Training in Tropical Diseases (TDR), TB Alliance, andSt. George’s, University of London, are pleased to announce the launch of the TB-Platform for Aggregation of Clinical TB Studies (TB-PACTS). “TB-PACTS is a valuable tool in the fight against the […]

April 18, 2016 Drug Development Partner News Press Releases Regulatory Science Research Resources Uncategorized clinical trials drug development TB-PACTS